Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezabenlimab and Afatinib in Refractory ESCC (BEAR)
NCT04839471Phase 2Completed
- Sponsor
- National Health Research Institutes
- Start
- Aug 2021
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
A Phase 2 trial of ezabenlimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by National Health Research Institutes. Started Aug 2021; status: completed.
02
Drugs
ezabenlimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04839471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839471.